After the HHS suggested changes to drug rebates in Medicare and Medicaid last week, HHS Secretary Alex Azar urged Congress to take a more radical step: Expand the proposal into commercial insurance, too. But is that what Azar really wants?
read moreThe moment Allergan has been dreading has arrived. Evolus snagged its FDA nod for a brand-new rival to Allergan’s lead moneymaker, Botox. More: Evolus' Botox competitor is here. Will it dent Allergan's sales? Source: fierce
read moreAnother Chinese drugmaker has run afoul of the FDA. After banning the imports of Hangzhou Guoguang Touring Commodity in October, the agency has now slapped its finished pharmaceutical plant with a warning letter. More: FDA finds big issue with Chinese
read moreUnitedHealthcare’s pharmacy benefits outfit OptumRx picked Amgen and Eli Lilly’s next-generation migraine drugs for its preferred coverage list, putting Teva’s Ajovy on the back foot in competing for the PBM’s patients. More: When 2 out of 3 is bad: Teva
read moreThe US Food and Drug Administration (FDA) has rejected Alkermes’ filing for ALKS 5461 in major depressive disorder (MDD), asking for more clinical data. More: FDA rejects Alkermes' depressive disorder drug Source: News
read moreSix medicines have taken a giant leap toward winning approval in Europe having won the backing of the European Medicines Agency’s (EMA) human medicines committee (CHMP). More: Migraine treatment Ajovy among CHMP’s six endorsed medicines Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals